Lung infiltration adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 8,683 adverse event reports that record the MedDRA preferred term Lung infiltration. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 182 reports in the 12 months to June 2026 and 219 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,336 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 182 (under 0.1%) record this term. Reports for male patients were 45.1% of the reports that record this term and 34.6% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 119 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Lung infiltration name as a suspect product, in order of name
Drug	Class	Reports with this term
Adalimumab	Tumor necrosis factor blocker	32
Afinitor	Kinase inhibitor	150
Albuterol	beta2-Adrenergic agonist	35
Albuterol sulfate	beta2-Adrenergic agonist	57
Alendronate sodium	Bisphosphonate	34
Alimta	Folate analog metabolic inhibitor	26
Allopurinol	Xanthine oxidase inhibitor	27
Alvesco		46
Amiodarone		42
Amiodarone hcl		35
Amlodipine	Calcium channel blocker	42
Aredia		149
Aspirin	Nonsteroidal anti-inflammatory drug	37
Avastin	Vascular endothelial growth factor inhibitor	55
Azacitidine	Nucleoside metabolic inhibitor	25
Azathioprine	Purine antimetabolite	130
Azithromycin	Macrolide antimicrobial	31
Bamlanivimab		34
Bevacizumab	Vascular endothelial growth factor inhibitor	62
Bleomycin	Cytoprotective agent	28
Breo Ellipta	Corticosteroid	41
Carboplatin	Platinum-based drug	117
Ceftriaxone	Cephalosporin antibacterial	25
Cetuximab	Epidermal growth factor receptor antagonist	27
Ciprofloxacin	Fluoroquinolone antibacterial	38
Cisplatin	Platinum-based drug	106
Cubicin		32
Cyclophosphamide	Alkylating drug	351
Cyclosporine	Calcineurin inhibitor immunosuppressant	137
Cytarabine	Nucleoside metabolic inhibitor	245
Daptomycin		32
Daunorubicin		46
Daunorubicin hydrochloride	Anthracycline topoisomerase inhibitor	52
Dexamethasone	Corticosteroid	184
Digoxin	Cardiac glycoside	71
Docetaxel	Microtubule inhibitor	83
Doxorubicin	Anthracycline topoisomerase inhibitor	110
Doxorubicin hydrochloride	Anthracycline topoisomerase inhibitor	109
Dupixent	Interleukin-4 receptor alpha antagonist	32
Enbrel	Tumor necrosis factor blocker	89
Etoposide	Topoisomerase inhibitor	150
Everolimus	Kinase inhibitor	51
Exjade	Iron chelator	46
Fentanyl	Opioid agonist	37
Fludarabine	Nucleoside metabolic inhibitor	34
Fludarabine phosphate	Nucleoside metabolic inhibitor	32
Fluorouracil	Nucleoside metabolic inhibitor	63
Fosamax	Bisphosphonate	91
Furosemide	Loop diuretic	28
Gemcitabine	Nucleoside metabolic inhibitor	61
Gemzar		50
Gleevec	Kinase inhibitor	47
Herceptin	HER2/neu receptor antagonist	82
Humira		252
Hydroxychloroquine	Antimalarial	29
Ibuprofen	Nonsteroidal anti-inflammatory drug	49
Imbruvica	Kinase inhibitor	36
Infliximab	Tumor necrosis factor blocker	36
Iressa	Kinase inhibitor	26
Jakafi	Janus kinase inhibitor	26
Keytruda	Programmed death Receptor-1 blocking antibody	40
Leflunomide	Antirheumatic agent	28
Lenalidomide	Thalidomide analog	33
Letrozole	Aromatase inhibitor	30
Leucovorin calcium	Folate analog	27
Mabthera		59
Melphalan	Alkylating drug	52
Mepolizumab	Interleukin-5 antagonist	33
Meropenem	Penem antibacterial	28
Methotrexate	Folate analog metabolic inhibitor	308
Methotrexate sodium	Folate analog metabolic inhibitor	47
Methylprednisolone	Corticosteroid	90
Montelukast	Leukotriene receptor antagonist	27
Mycophenolate mofetil	Antimetabolite immunosuppressant	161
Neoral	Calcineurin inhibitor immunosuppressant	34
Neulasta	Leukocyte growth factor	33
Neupogen	Leukocyte growth factor	35
Nivolumab	Programmed death Receptor-1 blocking antibody	31
Nucala	Interleukin-5 antagonist	33
Nuvaring	Estrogen	54
Opdivo	Programmed death Receptor-1 blocking antibody	25
Opsumit	Endothelin receptor antagonist	41
Oxaliplatin	Platinum-based drug	72
Paclitaxel	Microtubule inhibitor	96
Pembrolizumab	Programmed death Receptor-1 blocking antibody	33
Perjeta	HER2/neu receptor antagonist	27
Potassium chloride	Osmotic laxative	31
Prednisolone	Corticosteroid	212
Prednisone	Corticosteroid	350
Prograf	Calcineurin inhibitor immunosuppressant	31
Ramipril	Angiotensin converting enzyme inhibitor	45
Rapamune		31
Remicade	Tumor necrosis factor blocker	104
Revlimid	Thalidomide analog	86
Rituxan	CD20-directed cytolytic antibody	56
Rituximab	CD20-directed cytolytic antibody	243
Salbutamol		26
Singulair	Leukotriene receptor antagonist	45
Soliris	Complement inhibitor	27
Tacrolimus	Calcineurin inhibitor immunosuppressant	127
Tarceva		25
Tasigna	Kinase inhibitor	25
Taxol		54
Taxotere		65
Thalidomide		26
Thalomid		38
Tiotropium bromide	Anticholinergic	37
Tracleer	Endothelin receptor antagonist	28
Uniphyl		32
Vancomycin	Glycopeptide antibacterial	28
Velcade	Proteasome inhibitor	80
Venclexta	BCL-2 inhibitor	26
Venetoclax	BCL-2 inhibitor	43
Vincristine		147
Vincristine sulfate	Vinca alkaloid	80
Vioxx		73
Voriconazole	Azole antifungal	31
Xolair	Anti-IgE	31
Zometa		232

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 43 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Lung infiltration name, in order of name
Class	Reports with this term
Alkylating drug	545
Angiotensin converting enzyme inhibitor	56
Anthracycline topoisomerase inhibitor	288
Anti-epileptic agent	69
Anticholinergic	51
Antimetabolite immunosuppressant	202
Aromatase inhibitor	70
Atypical antipsychotic	82
Azole antifungal	78
BCL-2 inhibitor	69
beta2-Adrenergic agonist	95
Bisphosphonate	142
Calcineurin inhibitor immunosuppressant	338
Cardiac glycoside	73
CD20-directed cytolytic antibody	336
Cephalosporin antibacterial	60
Corticosteroid	952
Endothelin receptor antagonist	77
Estrogen	60
Fluoroquinolone antibacterial	61
Folate analog metabolic inhibitor	405
HER2/neu receptor antagonist	136
HMG-CoA reductase inhibitor	74
Interleukin-5 antagonist	66
Janus kinase inhibitor	52
Kinase inhibitor	646
Leukocyte growth factor	89
Leukotriene receptor antagonist	80
Microtubule inhibitor	186
Nonsteroidal anti-inflammatory drug	129
Nucleoside metabolic inhibitor	569
Opioid agonist	93
Osmotic laxative	51
Penicillin-class antibacterial	67
Platinum-based drug	295
Programmed death Receptor-1 blocking antibody	136
Proteasome inhibitor	119
Purine antimetabolite	140
Thalidomide analog	129
Topoisomerase inhibitor	168
Tumor necrosis factor blocker	294
Vascular endothelial growth factor inhibitor	117
Vinca alkaloid	100

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Lung infiltration, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Lung infiltration
Age	Reports	Share
Under 2	67	0.8%
2 to 11	181	2.1%
12 to 17	145	1.7%
18 to 44	1,206	13.9%
45 to 64	2,283	26.3%
65 to 74	1,470	16.9%
75 and over	1,012	11.7%
Age not given	2,319	26.7%

Sex of the patient in the reports that record Lung infiltration
Sex	Reports	Share
Female	4,154	47.8%
Male	3,916	45.1%
Unknown or not given	613	7.1%

Age and sex are as the report gives them. 47% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Lung infiltration: adverse event reports that record this term. https://reportedreactions.com/reaction/lung-infiltration/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Lung infiltration mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page